Drug reference
Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production. Endocrine system
PDF page 801
ZOLADEX LA ® Locally advanced prostate cancer as an alternative to surgical castration | Adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer ▶BY SUBCUTANEOUS INJECTION ▶Adult: 10.8 mg every 12 weeks, to be administered into the anterior abdominal wall ZOLADEX ® Locally advanced prostate cancer as an alternative to surgical castration | Adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer | Advanced breast cancer | Oestrogen-receptor-positive early breast cancer ▶BY SUBCUTANEOUS INJECTION ▶Adult: 3.6 mg every 28 days, to be administered into the anterior abdominal wall Endometriosis ▶BY SUBCUTANEOUS INJECTION ▶Adult: 3.6 mg every 28 days maximum duration of treatment 6 months (do not repeat), to be administered into the anterior abdominal wall Endometrial thinning before intra-uterine surgery ▶BY SUBCUTANEOUS INJECTION ▶Adult: 3.6 mg, dose may be repeated after 28 days if uterus is large or to allow flexible surgical timing, to be administered into the anterior abdominal wall Before surgery in women who have anaemia due to uterine fibroids ▶BY SUBCUTANEOUS INJECTION ▶Adult: 3.6 mg every 28 days maximum duration of treatment 3 months, to be given with supplementary iron, to be administered into the anterior abdominal wall Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (after exclusion of pregnancy) (under expert supervision) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 3.6 mg, dose given to achieve pituitary down- regulation (usually 1–3 weeks) then gonadotrophin is administered (stopping gonadotrophin on administration of chorionic gonadotrophin at appropriate stage of follicular development), to be administered into the anterior abdominal wall
PDF page 801
Undiagnosed vaginal bleeding. use longer than 6 months in endometriosis (do not repeat)
PDF page 801
Depression. diabetes. hypertension. patients with metabolic bone disease (decrease in bone mineral density can occur). polycystic ovarian disease. risk of spinal cord compression in men. risk of ureteric obstruction in men
PDF page 801
▶Common or very common Alopecia. arthralgia. bone pain. breast abnormalities. depression. glucose tolerance impaired. gynaecomastia. headache. heart failure. hot flush. hyperhidrosis. mood altered. myocardial infarction . neoplasm complications. paraesthesia. sexual dysfunction. skin reactions. spinal cord compression. vulvovaginal disorders. weight increased ▶Uncommon Hypercalcaemia (in women). ureteral obstruction Endocrine system ▶Rare or very rare Ovarian and fallopian tube disorders. pituitary haemorrhage. pituitary tumour. psychotic disorder ▶Frequency not known Abdominal cramps. body hair change . constipation. diarrhoea. fatigue. hepatic function abnormal. interstitial pneumonia. muscle complaints. nausea. nervousness. peripheral oedema (when used for gynaecological conditions). premature menopause. pulmonary embolism. QT interval prolongation. sleep disorder. uterine leiomyoma degeneration. voice alteration. vomiting. vulvovaginal infection. withdrawal bleed SIDE-EFFECTS, FURTHER INFORMATION Tumour flare can occur when androgen deprivation therapy is initiated.
PDF page 802
Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.
PDF page 802
Avoid.
PDF page 802
Avoid.
PDF page 802
Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy for prostate cancer.
PDF page 802
Rotate injection site to prevent atrophy and nodule formation.
PDF page 802
There can be variation in the licensing of different medicines containing the same drug. Implant ▶Zoladex (AstraZeneca UK Ltd) Goserelin (as Goserelin acetate) 3.6 mg Zoladex 3.6mg implant SafeSystem pre-filled syringes | 1 pre-filled disposable injection P £70.00 DT = £70.00 ▶Zoladex LA (AstraZeneca UK Ltd) Goserelin (as Goserelin acetate) 10.8 mg Zoladex LA 10.8mg implant SafeSystem pre-filled syringes | 1 pre-filled disposable injection P £235.00 DT = £235.00
PDF page 802
10.8 mg every 12 weeks, to be administered into
First-line fragment. Read the complete Indications and Dose section above.
PDF page 801
3.6 mg every 28 days, to be administered into
First-line fragment. Read the complete Indications and Dose section above.
PDF page 801
3.6 mg every 28 days maximum duration of
First-line fragment. Read the complete Indications and Dose section above.
PDF page 801
3.6 mg, dose may be repeated after 28 days if
First-line fragment. Read the complete Indications and Dose section above.
PDF page 801
3.6 mg every 28 days maximum duration of
First-line fragment. Read the complete Indications and Dose section above.
PDF page 801
3.6 mg, dose given to achieve pituitary down-
First-line fragment. Read the complete Indications and Dose section above.
PDF page 801
